Shopping Cart
Remove All
Your shopping cart is currently empty
Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein combining human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin, and has demonstrated anticancer activity [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein combining human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin, and has demonstrated anticancer activity [1]. |
| In vivo | Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; female NMRI nude mice MiaPaca-A2 xenografts) exhibited antitumor activity against established pancreatic cancer [1]. |
| Synonyms | L19-IL2 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | EDB |
| Cas No. | 1957239-90-5 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.